At a glance
ClinicalIndex Comparison RecordN/ACompleted· 110 enrolled
Drug / intervention
Covera(TM) Vascular Covered Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Multi-Center Clinical Study of the Bard® COVERA™ Arteriovenous (AV) Stent Graft in the Treatment of Stenosis at the Graft-Vein Anastomosis of AV Graft Circuits (AVeVA)
In Brief
A clinical study evaluating Covera(TM) Vascular Covered Stent for Stenosis and Restenosis. Completed, enrolled 110 participants across 16 sites.
Detailed Summary
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStenosis, Restenosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionAug 2017
Study CompletionMar 2019
TodayJul 2026
First PostedJun 6, 2016
Enrollment StartJul 1, 2016
Primary CompletionAug 1, 2017
Study CompletionMar 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.1 years ago
Interventions
Covera(TM) Vascular Covered Stentdevice
Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.